Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Aflibercept for Macular Edema from RAM
NCT02403128Phase 1Unknown
- Start
- May 2015
- Primary completion
- Feb 2020
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aflibercept in macular edema and Retinal artery macroaneurysm (RAM). Primary endpoint: Incidence and severity of ocular and systemic adverse events at 6 months. Status: unknown.
02
Drugs
aflibercept
03
Conditions
macular edemaRetinal artery macroaneurysm (RAM)
Beyond the preview
Go deeper on NCT02403128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02403128.